The nasal drug delivery market was valued at USD 52,998.5 million in 2018 and is projected to reach USD 81.1 Billion at 7.4% CAGR during the forecaast period 2023-2032.
In July 2021, GlaxoSmithKline announced that the US FDA had sanctioned Nucala (mepolizumab), a monoclonal antibody used for sufferers of chronic rhinosinusitis with nasal polyps.
Aptar Pharma’s subsidiary company Nanopharm collaborated with Fluidda in September 2022 to speed up approvals via an alternative bioequivalence pathway by harnessing their proprietary technology platforms for OIDPs (oral inhalation drug products) under abbreviated new drug application (ANDA) guidelines of the United States FDA.
SaNOtize Research & Development Corp partnered with Glenmark Pharmaceuticals in February 2022 to provide better treatment and care for COVID-19-infected adults in India by launching a nasal spray. This FabiSpray solution is cleared by the Drugs Controller General of India (DCGI) and can be bought in all retail pharmacies.
Catalent had its nasal capabilities enhanced at its Morrisville, Research Triangle Park (RTP), North Carolina, in April 2022. One of them is for administration of drugs from the nose to the brain, which bypasses systemic routes, and another one is for delivery of systemically acting drugs as alternative routes and offers various services related to unit and bi-dose nasal spray product development/manufacturing.
Leading provider of drug delivery systems, Aptar Pharma, unveiled Unidose+, a platform specifically developed for high-viscosity and challenging-to-formulate drugs, in October 2023.
In September 2023, Vectura Group signed a collaboration agreement with ALX Oncology to develop and market a novel formulation of ALX148 as a nasal spray targeting head and neck cancers.
The US FDA approved AstraZeneca’s RINVOQ nasal spray—the first ever IL-12/23 inhibitor meant for moderate-to-severe chronic rhinosinusitis alongside nasal polyps—on August 2023.
Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.
Factors such as the painless drug administration, development of new technological nasal drug delivery devices, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists.
However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the market growth.
The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.
The global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.
The global market has been segmented into drops, sprays, powder, gels, and ointments.
The global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.
The global market has been segmented into spray, nebulizers, inhalers, and others.
The global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
The global market, by end user, has been divided into home care settings and hospitals & clinics.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region.
Key Players
Regional Market Summary
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.
Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.
Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.
Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.
Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.
The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.
Intended Audience
| Report Attribute/Metric | Details |
| Â Â Market Size | Â USD 81.1 Billion |
| Â Â CAGR | Â Â 7.4% (2023-2030) |
| Â Â Base Year | Â Â 2021 |
| Â Â Forecast Period | Â Â 2023-2032 |
| Â Â Historical Data | Â Â 2020 |
| Â Â Forecast Units | Â Â Value (USD Million) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Drug Type, Dosage Form, Basis of System, Therapeutic Applications, End User |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
|   Key Vendors |   GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) |
| Â Â Key Market Opportunities | Â Â The Increasing number of patient population |
| Â Â Key Market Drivers | Â Â Factors such as the painless drug administration, development of new technological nasal drug delivery devices |
Nasal Drug Delivery Market Highlights:
Frequently Asked Questions (FAQ) :
Nasal drug delivery market projected to grow at approximately 7.4% CAGR during the assessment period (2023-2032).
Nasal drug delivery market had valued at around USD 52,998.5 MN in 2018.
Development of new technological nasal drug delivery devices and the increasing number of patient population with respiratory problem, are major tailwinds pushing the growth of the global nasal drug delivery market.
North America holds the largest share in the global nasal drug delivery market, followed by Europe and the Asia Pacific, respectively.
AstraZeneca (UK), 3M COMPANY (US), GlaxoSmithKline Plc. (UK), Novartis AG (UK), Pfizer, Inc. (US), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), Becton Dickson & Company (US), Sanofi-Aventis (UK), Cadila Pharmaceuticals (India), Merck & Co. (US), and Aegis Therapeutics LLC (US), are some of the top players operating in the global nasal drug delivery market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
